Fluorescent rhodamine-labeled thyroid hormone derivatives Synthesis and binding to the thyroid hormone nuclear receptor by Cheng, Sheue-yann et al.
Volume 100, number I FEBS LETTERS April 1979 
FLUORESCENT RHODAMINE-LABELED THYROID HORMONE DERIVATIVES 
Synthesis and binding to the thyroid hormone nuclear receptor 
Sheue-yann CHENG, Norman L. EBERHARDT”, Jacob ROBBINS, John D. BAXTER* and Ira PASTAN’ 
ClinicalEndocrinology Branch,NationalInstirute ofArthritis,Metabolism and DigestiveDiseases, ‘Laboratoy ofiWolecularBiology, 
National Cancer Institute, National Institutes of Health, Bethesda, MD 20014 and *Endocrine Research Division, Department of 
Medicine, Biochemistry and Biophysics, and Metabolic Research Unit, University of California, San Francisco, CA 94143, USA 
Received 17 January 1979 
1. Introduction 
Studies of the transport, intracellular distribution 
and interaction of thyroid hormones with specific 
subcellular components have depended upon the use 
of radiolabeled hormones. Application of this 
methodology to the study of transport in intact cells, 
however, is limited because of the difficulties in 
differentiating transported hormone from bound 
hormone at the cell surface. Therefore, it is important 
to devise alternate techniques for studying the trans- 
port of thyroid hormones in intact cells. A highly 
sensitive technique termed “video intensification 
microscopy’has been used [l-3] to study the binding 
and ~te~~ation of fluorescence-labeled peptide 
hormones and proteins in living cells. To apply this 
technique to thyroid hormones we have synthesized 
rhodamine-labeled derivations of iodothyronines 
directly to visualize their uptake, transport and 
distribution in cells. 
To determine if the derivatives retained biolo~c~ 
specificity, we studied their interaction with the 
thyroid hormone nuclear receptor [7]. A growing 
body of evidence indicates that many responses of 
thyroid hormones may be explained by their interac- 
tion with a chromatin-localized receptor which sub- 
sequently influences the expression of specific genes 
Abbreviations: T,, 3,5,3’-tri-iodo-L-thyronine; T,, 3,5,3’,5’- 
tetraiodo-L-thyronine; To, L-thyronine; [14C]T0, 4”hydroxy- 
phenoxy-[ U-“C] tyrosine; TRITC, tetramethyl rhodamine 
isothiocyanate; TLC, thin-layer chromatography 
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(reviewed [4-61). Studies from a number of labora- 
tories indicate that the receptor binds Ts, T4 and 
other thyroid hormone analogues in proportion to 
their biological activity 17%IO]. 
2. Materials and methods 
[‘251]T3 and [‘251]T4, with spec. act. 1300 &i/@g 
and 1000 &i/pg, respectively, were obtained from 
New England Nuclear. Non-radioactive T4 and T3 
were purchased from CalBiochem. T, was kindly 
provided by Dr Paul Block, River Research, 4059 
River Road, Toledo, OH 43614. TRITC (mixed 
isomers) was obtained from Research Organic, 
Cleveland, OH. Preparative and analytical thin-layer 
plates were from Whatman, New Jersey. Solvent 
systems for TLC were: (A) upper phase of ethyl 
acetate:methanol:water (5:2:3, v/v/v) which was 
adjusted to pH 10.5 with the addition of triethyl- 
amine;(B)upper phase of ethyl acetate:me~~ol:2 N 
N&OH (5:2:3, v/v/v); (C) hexane:tert-amyl alcohol: 
methanol:water (1:6:2: 1; v/v/v/v). Absorption spectra 
were measured in a Gary 14 spectrophotometer. 
2.1. Synthesis of (‘251]T3- land [1251JT4-rhodamine 
The synthetic scheme for [“‘I] To-rhodamine is 
illustrated in fig.1. In a typical synthesis, 3 pmol 
each of TRITC and [1251]T3 (0.5 Ci/mol) in 0.1 ml 
pyridine:water:triethylamine (9: 1 .5:0.1 , v/v/v) were 
reacted for 1 h at room temperature. Purification was 
carried out by repeated preparative TLC in solvent 
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Fig.1. Synthetic scheme for the preparation of [ “‘I]T,-rhodamine. 
system A. The purple radiolabeled bands with RF 
-0.25 and -0.27, designated as Ts-rhodamine- and 
T,-rhodamine-II, respectively, were eluted with 
methanol. After evaporation of methanol, the dry 
residues were stored in the dark at -20°F and were 
stable for periods of at least 6 months. The radio- 
labeled derivatives were used as markers for purifica- 
tion. The specific activity was maintained sufficiently 
low so that subsequent nuclear receptor binding assays 
utilizing [ 12’ I] ‘T3 were not affected. 
[ 1251] T4-rhodamine was synthesized and purified 
2.3. Binding to thyroid hormone nuclear receptors 
The binding assays were carried out as detailed 
in [7]. 
3. Results and discussion 
similarly except that the radiolabeled bands eluted 
had RF -0.13 and -0.15 were designated as 
[ 1251] T4-rhodamine- and [“‘I] T4-rhodamine-II, 
respectively. 
2.2. Synthesis of / 14C] To-rhodamine 
[ 14C] To was synthesized by coupling of 3,5-diiodo- 
[U-14C]tyrosine with 4-hydroxy-3 J-di-iodophenyl- 
pyruvic acid to form “C-labeled T4 [ 1 l] followed by 
subsequent de-iodination. 14C-Labeled T4 was first 
deiodinated with a mixture of hypophosphorous acid 
and hydriodic acid to form 14C-labeled 3,5-di-iodo- 
thyronine [ 121 which was further de-iodinated to 
[‘“Cl To by catalytic hydrogenation in the presence 
of 5% Pd on alumina. 
The thyroid hormones, Ts and T4, and the 
biologically inactive To were attached through their 
amino groups to tetramethyl rhodamine via a thiourea 
linkage (fig.1). Since the starting material, TRITC, 
was commercially obtained as a mixture of 4’ and 5’ 
isomers, two isomeric derivatives of Ts would be 
expected. Two radiolabeled rhodamine-containing 
derivatives with similar chromatographic mobilities 
were observed during purification and were sub- 
sequently isolated. The slow- and fast-migrating 
derivatives, Ts-rhodamine- and Ts-rhodamine- 
(see section 2) respectively, presumably represent 
the attachment of T3 to the 4’ or 5’ position of 
rhodamine. The formation of the Ts-rhodamine 
conjugate was established by: 
(i) Its chromatographic mobility which is lower 
than either of the initial reactants; 
(ii) The presence of Ts as determined by incorpora- 
tion of “‘1 radioactivity, 
The method used to covalently link To to (iii) Its characteristic absorption spectrum which is 
rhodamine was the same as described for the synthesis consistent with the presence of rhodamine and 
of Ta- or T,-rhodamine. However, solvent system B T3 moieties. Purity was established by TLC on 
was used in preparative TLC and the eluted band had silica gel and cellulose plates in solvent system 
RF -0.15. The unresolved 4’ and 5’ isomeric mixture A and C. The absence of contamination by free 
of To-rhodamine was used in the nuclear receptor hormone was confirmed by autoradiography and 
binding assays. counting segments of the thin-layer chromato- 
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Fig.2. Competition of [IZSI]T, binding to the solubilized thyroid 
hormone nuclear eceptor by unlabeled T, (circles), T, (open 
squares), T -rhodamine- (solid diamonds), T,-rhodamine- 
(solid triangles) and To-rhodamine (solid squares). The nuclear 
receptor [7] was so&biked from purified rat liver nuclei and 
was incubated with [ izsI]T, at 1 nM final cone. with varying 
concentrations of the indicated competitors for 2 h at 22°C. 
Bound hormone was separated from free hormone by passage 
of the incubation mixtures over 2.0 ml Sephadex G-25 columns 
and subsequent determination of bound radioactivity. The 
individual data points represent he average of duplicate 
‘determinations. 
grams. The purity of [lz51]T4- and [14C]To- 
rhodamine was established similarly. 
Figure 2 shows the results of the competition of 
[lz51] T3 binding to the receptor by unlabeled 
Tf, T4, TV-rhodam~e-II, TV-rhodam~e-II and 
To-rhodamine. These data indicate that TS- and 
T4-rhodamine- both bind to the receptor with 
affinities -2 orders of magnitude lower than TB. The 
calculated [7] K, values for the binding of T,-rho- 
damine-II and TV-rhodamine-II to the receptor are 
20.3 nM and 70.8 nM, respectively. Thus, the 
derivatives bind to the receptor at concentrations 
which can be reasonably achieved in intact cells. 
The data also indicate that TB-rhodamine- binds to 
the receptor more avidly than T4-rhodamine-11, 
although the difference in the af~nities of the two 
derivatives is somewhat smaller than with the parent 
hormones (fig.2) [7-lo]. In addition, To-rhodamine 
does not interact with the receptor over the concen- 
tration range employed in these studies. Since 15, is 
biologically inactive, we conclude that the binding of 
the thyroid hormone-rhodamine derivatives to the 
receptor results from biospecific interactions. 
The slow- and fast-migrating T3- and T,-rhodamine 
derivatives possess lightly different affinities for the 
receptor (table 1). The fast-migrating derivatives 
have higher affinities than the slow-migrating deriva- 
tives. Although the exact linkage position for each of 
the derivatives is u~l~own, the data indicate that the 
orientation of rhodamine with respect to the hormone 
has a minor influence on the binding affinities of the 
derivatives to the receptor. 
The synthesis of fluorescein-labeled T4 has been 
reported [ 13 1; however, its physico-chemical properties 
and biological specificity have not been examined. 
Furthermore, fluorescein has a relatively faster 
fluorescence bleaching rate than rhodamine thereby 
decreasing the sensitivity of its detection by ‘video 
intensification microscopy’. 
Our data indicate that the rhodamine-labeled 
derivatives of thyroid hormones interact with nuclear 
thyroid hormone receptors in a manner which reflects 
the binding specificities of the parent hormones. 
These data therefore indicate that these derivatives 
may be useful in studies of thyroid hormone interac- 
tion with intact cells. 
Table 1 
Apparent equilibrium dissociation constants for the binding 
of rhodamine-labeled thyroid hormones to the 
nuclear receptor 
Rhodamine-labeled Kd 
thyroid hormones (nm)a 
T,-rhodamine- 20.3 
T,-rhodamine- 38.3 
T,-rhodamine- 70.8 
TV-rhod~~e-I 203 
a The dissociation constants were calculated from the equa- 
tion: 
where Kd = apparent dissociation constant of the competitor, 
C,, = concentration of competitor required to produce 50% 
inhibition, KT = dissociation constant of T,, and T = con- 
centrations of I’2SI]T, utilized in the assay. The receptor 
preparation utilized in these studies had a T, Kd of 
0.221 nM as determined by Scatchard analysis 
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